Mumbai, April 18:Aurobindo Pharma has received final approval for its Venlafaxine Extended Release Capsules from the US Food & Drug Administration (USFDA), the company informed Bombay Stock Exchange (BSE) today.
These capsules are prescribed for treatment of major depressive disorders and falls under the Neurological therapeutic category.
The product has a market size of approximately USD 2.4 billion for the twelve months that ended in September 2010.
Among the largest ‘Vertically Integrated’ pharmaceutical companies in India, Aurobindo has a robust product portfolio spread over major product areas, encompassing Antibiotics, Gastroenterologicals, Anti-Diabetics and Anti-Allergic with approved manufacturing facilities by USFDA, it added.
———————UNI——————-